XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...
Cardiac Substructure Radiation Dose and Risk of Late Cardiac Disease in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study Eligible participants had mCRPC that progressed ...
The advent of more effective treatment combinations for metastatic hormone-sensitive prostate cancer (mHSPC) has been built on successes in therapy development for metastatic, castration-resistant ...
NPR's Ayesha Rascoe talks with urologist Ben Davies about the prevalence of prostate cancer, new treatments, and patients' reluctance to discuss the disease and its aftermath. Early last week, after ...
The phase 3 ARASTEP trial will investigate Nubeqa plus androgen-deprivation therapy in certain patients with hormone-sensitive prostate cancer. Researchers are looking to enroll approximately 750 ...
Please provide your email address to receive an email when new articles are posted on . Adding radiation therapy to standard care significantly extended radiographic PFS but not OS. Radiation therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results